← ANALYST RATINGS · TIPRANKS
Puma Biotechnology (PBYI): analyst forecast and price target
Analyst consensus
Hold0 Buy1 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $6.00, the highest $6.00, the lowest $6.00. The average is −39.0% from the last price of $9.83.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $12.50+4.2% | Buy | +27.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $12.00+4.3% | Buy | +22.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $12.00+4.3% | Buy | +22.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $11.50+4.5% | Hold | +17.0% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $12.00+4.3% | Buy | +22.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $11.50+4.5% | Buy | +17.0% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | $5.00 → $6.00+20.0% | Hold | −39.0% | Reiterated | 07.08.26on TipRanks Aug 6 20:10 | +9.1%next day −2.4% · 5 days −1.3% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $2.00 | Sell | −79.7% | Reiterated | 07.11.25on TipRanks 07:55 | +22.1%next day −22.6% · 5 days −18.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Puma Biotechnology
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.00 at a price of $9.93 (−39.6%); now: $6.00 at $9.83 (−39.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.09 (from $0.09 to $0.09). Last quarter: $0.16.
Sales
Next quarter’s sales estimate — $58M (from $58M to $58M). Last quarter: $57M.
Best top-analyst consensus in the sector · Healthcare
About Puma Biotechnology
- CEO: Alan H. Auerbach
- Employees: 179
- 10880 Wilshire Boulevard, Los Angeles, CA, 90024, US
- www.pumabiotechnology.com
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Data from the stock’s TipRanks forecast page, read 64 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗